GlassScriptPhysician profile
Jacqueline Ward
NPI 1336103126
$1,388.45
in general payments reported to CMS, 2019-2025
25 companies · $758 in 2025
The $758 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.24 · 2024: $620 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $296.93 | 2024-2025 | |
| Astellas Pharma US INC | $189.17 | 2019-2025 | Veozah |
| Novo Nordisk INC | $159.74 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $116.87 | 2024-2025 | |
| Eisai INC. | $65.21 | 2025 | |
| Novartis Pharmaceuticals Corporation | $61.33 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.28 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $49.08 | 2024-2025 | Airsupra |
| Edwards Lifesciences Corporation | $39.25 | 2025 | Sapien 3 Ultra Resilia |
| Lilly USA, LLC | $35.01 | 2024-2025 | Mounjaro, Zepbound |
| Mayne Pharma Commercial LLC | $34.57 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.62 | 2024-2025 | Jardiance |
| Hologic Sales and Service, LLC | $33.32 | 2024 | Thinprep 2000 Processor, Aptima |
| Corcept Therapeutics | $29.17 | 2024 | Korlym |
| Exact Sciences Corporation | $24.51 | 2025 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23.46 | 2025 | |
| Alexion Pharmaceuticals, INC. | $22.79 | 2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $19.49 | 2025 | Recorlev |
| Radius Health, INC. | $19.17 | 2025 | Tymlos |
| Glaxosmithkline, LLC. | $17.73 | 2025 | Trelegy Ellipta |
| Abiomed | $14.74 | 2025 | |
| Merck Sharp & Dohme LLC | $14.38 | 2025 | Capvaxive, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $14.02 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $11.45 | 2025 | Voquezna |
| Cequr Corporation | $8.16 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.